Videoconsultation During Follow-Up Care of Patients with a Neuroendocrine Tumor. Abstract #1766

Introduction: Patients with a neuroendocrine tumor (NET) are increasingly treated in expert centers leading to longer travel times for medical consultations. Videoconsultation (VC) potentially allows remote guidance of patients.
Aim(s): The primary aim of this study is to assess feasibility of VC during follow-up care of NET patients.
Materials and methods: Twenty clinical stable patients received two VCs during follow-up care. Feasibility was assessed by calculation of participation/dropout rate and safety. Satisfaction questionnaires were filled out by patients and physicians. VC time, patient-reported travel time for an outpatient clinic visit and preference for type of consultation were noted.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Grietje Bouma

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1099 Niacin (vitamin B3) Suppletion in Patients with Serotonin Producing Neuroendocrine Tumors
Introduction: Tryptophan is the precursor of serotonin and niacin (vitamin B3), critical for normal cellular metabolism. Tryptophan and niacin can be deficient in patients with serotonin producing neuroendocrine tumors (NETs). Niacin deficiency can lead to symptoms including pellagra.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Grietje Bouma
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET
#1884 Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; A Feasibility Study
Introduction: Patients with a neuroendocrine tumor (NET) often have gastro-intestinal complaints due to somatostatin analogue (SSA), tumor mass, secretion of neuroendocrine amines or treatment. This can lead to impaired absorption of critical food components such as vitamins. Serotonin producing NET patients may also have low plasma tryptophan.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson